NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

GDTC

CytoMed Therapeutics Ltd

Apr 17 • 04:00PM ET

2.46

Dollar change +0.13
Percentage change 5.58	%

Healthcare • Biotechnology • Singapore • NASD

Peers: NTLA FATE CRSP EDIT ADAP CELU BLUE CLLS PSTX SGMO

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.20	Insider Own	58.14%	Shs Outstand	11.54M	Perf Week	-1.60%
Market Cap	28.39M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	4.83M	Perf Month	-6.55%
Income	-2.27M	PEG	-	EPS next Q	-	Inst Own	0.09%	Short Float	1.95%	Perf Quarter	2.93%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	450.67%	Short Ratio	4.37	Perf Half Y	18.27%
Book/sh	0.65	P/B	3.79	EPS next Y	-	ROA	-24.78%	Short Interest	0.09M	Perf Year	23.00%
Cash/sh	0.41	P/C	5.94	EPS next 5Y	-	ROE	-26.36%	52W Range	1.20 - 4.05	Perf YTD	-27.65%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-29.16%	52W High	-39.26%	Beta	-0.32
Dividend TTM	-	Quick Ratio	21.53	Sales past 5Y	-	Gross Margin	-	52W Low	105.00%	ATR (14)	0.22
Dividend Ex-Date	-	Current Ratio	21.53	EPS Y/Y TTM	29.75%	Oper. Margin	-	RSI (14)	49.89	Volatility	6.16% 9.43%
Employees	-	Debt/Eq	0.04	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	5.00
Option/Short	No / Yes	LT Debt/Eq	0.04	EPS Q/Q	50.04%	Payout	-	Rel Volume	0.05	Prev Close	2.33
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	21.54K	Price	2.46
SMA20	2.42%	SMA50	-4.48%	SMA200	8.30%	Trades		Volume	1,162	Change	5.58%

Feb-06-25 07:20AM	CytoMed Therapeutics announces Chairman's Letter to the Company's shareholders (GlobeNewswire)
Jan-07-25 07:58AM	CytoMed and SunAct Collaborate on Cancer Immunotherapy Trials in India (TipRanks) -13.70%
06:45AM	CytoMed Therapeutics and SunAct to conduct solid tumour treatment trial in India (Clinical Trials Arena)
Jan-06-25 07:00AM	CytoMed Therapeutics signs Business and Research Collaboration Agreement with India's SunAct Cancer Institute Private Limited to advance use of allogeneic off-the-shelf Gamma Delta T Cells for treatment of solid cancers in a proposed Phase 2 clinical trial in India (GlobeNewswire)
07:00AM	CytoMed Therapeutics signs Business & Research Collaboration Agreement with Indias SunAct Cancer Institute Private Limited to advance use of allogeneic off-the-shelf Gamma Delta T Cells for treatment of solid cancers in a proposed Phase 2 clinical trial in India (GlobeNewswire)
07:00AM	Loading…
Nov-20-24 07:00AM	Update on Clinical Milestone - CytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies (GlobeNewswire) +9.99%
Oct-07-24 07:00AM	CytoMed Therapeutics' first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial Grant (GlobeNewswire) +10.04%
Oct-04-24 07:27AM	CytoMed Acquires Cord Blood Assets, Eyes Regenerative Medicine (TipRanks) +7.94%
Oct-03-24 07:00AM	CytoMed Therapeutics completes cash acquisition of Cord Blood Banking Licence and Assets expanding CytoMed's strategy to cord blood-derived biologics through subsidiary, LongevityBank (GlobeNewswire)
Sep-30-24 07:00AM	CytoMed Therapeutics Reports Six Months Ended June 30, 2024 Financial Results and Provides Clinical and Corporate Updates (GlobeNewswire)
Sep-25-24 07:00AM	Presenting on the Emerging Growth Conference 75 Day 2 on September 26 (GlobeNewswire)
Sep-24-24 07:00AM	Presenting on the Emerging Growth Conference 75 Day 1 on September 25 Register Now (GlobeNewswire)
Aug-21-24 07:00AM	Presenting on the Emerging Growth Conference 74 Day 2 on August 22 Register Now (GlobeNewswire)
Aug-20-24 07:00AM	Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now (GlobeNewswire) -8.62%
Jul-17-24 07:00AM	Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now (GlobeNewswire) +14.29%
07:00AM	Loading…
07:00AM	CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (?d) T Cells Technology for Solid and Liquid Cancers (GlobeNewswire)
07:00AM	CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta ( ) T Cells Technology for Solid and Liquid Cancers (GlobeNewswire)
Jul-16-24 07:00AM	Presenting on the Emerging Growth Conference 73 Day 1 on July 17 Register Now (GlobeNewswire)
Mar-20-24 08:30AM	CytoMed Diversifies into Regenerative Medicine after Research Collaboration with Singapore's Sengkang General Hospital to Test Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Regeneration (ACCESSWIRE) -5.60%
Mar-18-24 06:00AM	CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision Therapies (GlobeNewswire) +5.63%
Mar-04-24 05:00AM	CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair (GlobeNewswire)
Jan-29-24 07:00AM	Malaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology (GlobeNewswire)
Dec-05-23 07:30AM	CytoMed Therapeutics Signs HOA and MOU to Advance Research on Allogeneic Gamma Delta T Cell Technology (PR Newswire)
Nov-17-23 09:21AM	CytoMed Therapeutics Reports First Half 2023 Financial Report and Provides Corporate Update (PR Newswire) -8.60%
Nov-14-23 07:47AM	CytoMed Therapeutics to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference (PR Newswire)
Oct-24-23 01:00PM	CytoMed Therapeutics Adds to its Intellectual Portfolio After Securing Chinese Patent for its Licensed iPSC-Based Technology (ACCESSWIRE) +5.04%
Sep-25-23 07:00AM	Chinese Patent Granted for CytoMed Therapeutics' Licensed iPSC-Based Technology (PR Newswire) +6.45%
Aug-29-23 09:00AM	CytoMed Expands Research Collaboration into China After Entering Into MOU (ACCESSWIRE)
Aug-17-23 07:30AM	CytoMed Therapeutics Limited to Present at the August 24th Virtual Investor Summit (Newsfile)
Aug-15-23 01:00PM	CytoMed Therapeutics Announces China Research Collaboration to Enhance its Allogeneic CAR T In Vivo Persistency (PR Newswire)
07:00AM	Loading…
Aug-01-23 07:00AM	Chinese Patent Granted for A*STAR Spinoff, CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology (PR Newswire)
Jul-27-23 09:00AM	CytoMed Therapeutics Announces U.S. Patent Granted For its Licensed, Novel CAR-Gamma Delta T Cell Technology (ACCESSWIRE)
Jul-14-23 10:52AM	Insiders Rewarded With S$77k Addition To Investment As CytoMed Therapeutics Stock Hits US$51m (Simply Wall St.)
Jul-06-23 07:00AM	A*STAR Spinoff CytoMed Therapeutics Announce a Patent for its Licensed CAR-Gamma Delta T Cell Technology Has Been Granted in the US (PR Newswire) +6.23%
Jun-28-23 09:00AM	CytoMed Therapeutics Collaborates With Cancer Treatment Center to Advance Its Unique CAR-T Technology (NewMediaWire) +7.02%
May-11-23 09:00AM	CytoMed Therapeutics to Ring Nasdaq Closing Bell (PR Newswire) -6.31%
May-09-23 10:07AM	CytoMed Therapeutics Limited Announces Collaboration with MD Anderson Cancer Center to Advance Allogeneic Off-the-Shelf Gamma Delta T Cells in Oncology (PR Newswire) -19.50%
Apr-13-23 08:00PM	CytoMed Therapeutics Limited Announces Pricing of Initial Public Offering (PR Newswire)

CytoMed Therapeutics Ltd. is a biopharmaceutical company, which engages in the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy, and undertaking the research and development of immune cell and stem cell-based therapy. It operates through the Malaysia and Singapore geographical segments. The company was founded by Chee Kong Choo on March 9, 2018 and is headquartered in Singapore.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
mDR Ltd	10% Owner	Mar 24 '25	Proposed Sale	2.66	86,410	229,850		Mar 24 12:03 PM
mDR Ltd	10% Owner	Nov 05 '24	Proposed Sale	2.31	115,400	265,997		Nov 04 12:13 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GDTC

CytoMed Therapeutics Ltd

Upgrade your FINVIZ experience